CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116 CNY | -4.32% |
|
-1.49% | -20.47% |
| Sales 2024 * | 16.55B 2.29B | Sales 2025 * | 18.63B 2.57B | Capitalization | 46.63B 6.44B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.23B 722M | Net income 2025 * | 5.93B 818M | EV / Sales 2024 * | 2.82 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.5 x |
| P/E ratio 2024 * |
8.95
x | P/E ratio 2025 * |
7.86
x | Employees | - |
| Yield 2024 * |
2.46% | Yield 2025 * |
2.31% | Free-Float | 68.45% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.32% | ||
| 1 week | -1.49% | ||
| Current month | -3.53% | ||
| 1 month | -11.19% | ||
| 3 months | -7.59% | ||
| 6 months | -14.23% | ||
| Current year | -20.47% |
1 week
115.26
123.38
1 month
115.26132.95
Current year
106.33147.21
1 year
106.33175.80
3 years
106.33523.00
5 years
106.33523.00
10 years
38.39523.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yun Tao Jiang
CEO | Chief Executive Officer | 50 | 14-12-31 |
Ji Ma
CHM | Chairman | 59 | 17-10-31 |
Xing Gong Zhu
DFI | Director of Finance/CFO | 57 | 02-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiu Feng Li
PRN | Corporate Officer/Principal | 55 | 08-07-31 |
Zhi Gang Wang
BRD | Director/Board Member | 52 | 14-12-28 |
Ji Ma
CHM | Chairman | 59 | 17-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.17% | 2 M€ | -19.84% | - | |
| 1.02% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 116 | -4.32% | 5,144,466 |
| 24-04-17 | 121.2 | +0.25% | 6,253,870 |
| 24-04-16 | 120.9 | -0.03% | 5,768,860 |
| 24-04-15 | 120.9 | +2.47% | 4,746,404 |
| 24-04-12 | 118 | +0.26% | 3,528,282 |
End-of-day quote Shenzhen S.E., April 17, 2024
More quotes
Changchun High-Tech Industry (Group) Inc. specializes in the manufacturing and marketing of biopharmaceutical products. Products include polyethylene glycol-based recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, lyophilized live varicella vaccines and rabies vaccines for human use.
Sector
Pharmaceuticals
Calendar
2024-04-19
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
116
CNY
Average target price
198.7
CNY
Spread / Average Target
+71.37%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.47% | 6.44B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +1.92% | 211B | |
| -0.53% | 203B | |
| -10.27% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 000661 Stock
